Article info

Download PDFPDF

Original article
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

Authors

  1. Correspondence to Vibeke Strand; vstrand{at}stanford.edu
View Full Text

Citation

Strand V, de Vlam K, Covarrubias-Cobos JA, et al
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

Publication history

  • Received August 24, 2018
  • Revision received October 5, 2018
  • Accepted October 13, 2018
  • First published January 11, 2019.
Online issue publication 
January 11, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.